liraglutide (Victoza, Saxenda): the foundational daily GLP-1

liraglutide is a 31-amino-acid acylated GLP-1 analog with a C16 palmitic-acid sidechain that binds albumin and supports once-daily subcutaneous dosing. it was the first daily GLP-1 receptor agonist to reach the market (Victoza, 2010), the first GLP-1 agent approved for chronic weight management (Saxenda, 2014), and the molecule that established the cardioprotective story for the class through the LEADER trial. generic liraglutide injection began entering the US market in 2024.

what is liraglutide?

liraglutide is engineered from human GLP-1(7-37) with a single amino acid substitution (Lys26 to Arg) and a C16 palmitic acid attached to Lys20 through a gamma-glutamic-acid spacer. the palmitate binds reversibly to circulating albumin, shields the peptide from proteolysis and renal filtration, and extends the half-life from about two minutes (native GLP-1) to roughly 13 hours.

the molecule was developed at Novo Nordisk in the late 1990s under the code NN2211. Knudsen and colleagues published the foundational chemistry and pharmacology in 2000, demonstrating that the C16 palmitate plus gamma-Glu linker preserved GLP-1 receptor binding while delivering the pharmacokinetic profile suitable for once-daily administration [1]. a single-dose phase 1 PK study by Elbrond and colleagues in 2002 confirmed a half-life of about 12 to 14 hours in healthy male subjects [2]. the daily dosing window was deliberate: long enough for adherent once-daily injection, short enough that dose adjustments, missed doses, and treatment cessation are all on a one-day timescale.

liraglutide is sold as Victoza (1.2 and 1.8 mg pens for type 2 diabetes) and Saxenda (3.0 mg pen for chronic weight management). its closest pharmacologic ancestor is twice-daily exenatide (Byetta, approved 2005), and its closest successor is once-weekly semaglutide (Ozempic, Wegovy, Rybelsus). liraglutide sits at the inflection point in the GLP-1 era and is the molecule that proved the daily-acylated-peptide platform worked.

how does it work?

liraglutide is a full agonist at the GLP-1 receptor, a class B G-protein-coupled receptor predominantly coupled to Gs, cAMP, and PKA signaling. it stimulates glucose-dependent insulin secretion, suppresses post-meal glucagon, slows gastric emptying, and reduces appetite through both central (hypothalamic arcuate POMC activation) and peripheral pathways.

the GLP-1 receptor is widely expressed: pancreatic beta cells (where it amplifies glucose-driven insulin release through the cAMP/PKA and cAMP/Epac2 pathways), alpha cells (where it suppresses inappropriate post-meal glucagon), gastric smooth muscle and enteric neurons (where it slows gastric emptying), hypothalamic arcuate POMC/CART neurons (satiety), brainstem NTS (satiety and nausea), and vascular endothelial and renal tubular cells (organ-protective effects). the glucose-dependence of insulin release is the molecular basis for the low intrinsic hypoglycemia risk: when plasma glucose drops below about 70 mg/dL, GLP-1 receptor agonism has minimal insulinotropic effect.

the weight-loss mechanism has both central and peripheral components. Secher and colleagues labeled liraglutide with a fluorescent tracer in rodents and showed it accesses the hypothalamic arcuate nucleus and drives POMC activation directly, anchoring the central appetite-suppression effect [3]. van Can and colleagues demonstrated pronounced gastric-emptying delay in humans that attenuates over 4 to 8 weeks of chronic dosing (tachyphylaxis at the gut motility endpoint), while subjective appetite reduction and energy-intake reductions persist [4]. the partition between central and peripheral contributions is probably not 100 percent settled but both clearly contribute.

what does the evidence show?

liraglutide is among the best-studied peptide drugs in the world. the LEAD program (six phase 3 trials) established efficacy in type 2 diabetes, the SCALE program demonstrated chronic weight management at the 3.0 mg dose, LEADER showed a 13 percent reduction in major adverse cardiovascular events in T2D with high CV risk, a renal substudy showed albuminuria reduction, and the Ellipse trial supported pediatric T2D approval.

the LEAD trials (LEAD-1 through LEAD-6, published 2009) systematically tested liraglutide across the T2D regimen landscape. LEAD-3 (Garber et al., Lancet 2009) compared liraglutide 1.8 mg monotherapy with glimepiride monotherapy over 52 weeks and showed an HbA1c reduction of about 1.1 percent with 2.5 kg weight loss versus 1.1 kg gain on glimepiride [5]. LEAD-6 (Buse et al., Lancet 2009) was the head-to-head against twice-daily exenatide and showed greater HbA1c reduction with fewer persistent nausea events on liraglutide. the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., NEJM 2015) randomized 3,731 adults without T2D to liraglutide 3.0 mg plus lifestyle versus placebo plus lifestyle for 56 weeks. mean weight change was -8.4 kg liraglutide versus -2.8 kg placebo, a placebo-adjusted difference of about 5.6 kg or roughly 6 percent additional weight loss beyond placebo [6]. SCALE Diabetes, SCALE Maintenance, SCALE OSA, and the 3-year SCALE Prediabetes extension (which showed a 79 percent reduction in new T2D diagnoses) round out the obesity program.

the LEADER trial (Marso et al., NEJM 2016) is the most important outcomes study. 9,340 adults with T2D and either established cardiovascular disease or high CV risk were randomized to liraglutide 1.8 mg or placebo on top of standard care, with median follow-up of 3.8 years. the primary composite endpoint (major adverse cardiovascular events: CV death, non-fatal MI, non-fatal stroke) occurred in 13.0 percent of the liraglutide arm versus 14.9 percent of the placebo arm, a hazard ratio of 0.87 (95% CI 0.78-0.97, p=0.01 for superiority). CV death and all-cause death also reduced significantly [7]. this was the second GLP-1 receptor agonist to demonstrate cardiovascular benefit and helped establish GLP-1 cardioprotection as a class principle.

a pre-specified renal substudy of LEADER (Mann et al., NEJM 2017) reported a composite renal outcome hazard ratio of 0.78 (95% CI 0.67-0.92), driven primarily by reduction in new persistent macroalbuminuria. the Ellipse trial (Tamborlane et al., NEJM 2019) randomized 134 patients aged 10 to 17 with T2D and supported pediatric approval. and the LEAN trial (Armstrong et al., Lancet 2016) was a small phase 2 in biopsy-confirmed NASH that reported NASH resolution in 39 percent of liraglutide arms versus 9 percent of placebo, pre-figuring the larger semaglutide NASH program but without progressing to a liraglutide MASH approval.

FDA and regulatory status

Victoza was FDA-approved in January 2010 for adults with type 2 diabetes. Saxenda was approved in December 2014 for chronic weight management in adults. pediatric T2D (age 10 and over) was added in 2019, and pediatric obesity (age 12-17) in 2020. the first generic liraglutide injection received FDA approval in 2024, ending Novo Nordisk's exclusivity. the label carries a boxed warning for thyroid C-cell tumors based on a rodent finding.

the regulatory journey was a series of firsts: Victoza was the first GLP-1 receptor agonist with a once-daily injectable profile to reach the US market, Saxenda was the first GLP-1 agent approved for chronic weight management, and pediatric T2D approval in 2019 made liraglutide the first non-insulin pharmacologic approved for type 2 diabetes in children since metformin. the EU and most major markets (UK, Canada, Australia, Japan, India, China) followed the US/EU pattern with mostly identical indications. liraglutide is not currently on the WHO Essential Medicines List (semaglutide was added in 2025; liraglutide was not).

the 2024 generic approval is genuinely consequential. it ends Novo Nordisk's market exclusivity, sets the stage for biosimilar competition, and may re-establish a price-driven niche for liraglutide even as semaglutide and tirzepatide dominate new prescriptions for both T2D and obesity. liraglutide is not specifically listed on the WADA Prohibited List, though sport-specific rules can apply in weight-class sports.

safety profile and side effects

gastrointestinal events dominate: nausea (25-40 percent during early titration, falling to 5-10 percent by week 12), vomiting, diarrhea, and constipation. serious but rare risks include pancreatitis, gallbladder disease, dehydration-mediated acute kidney injury, and a boxed warning for thyroid C-cell tumors based on rodent data that has not produced a clear human signal in 15 years of surveillance.

GI tolerability is the dominant discontinuation driver across LEAD, SCALE, and LEADER. small frequent meals, lower fat content, hydration, and judicious antiemetics during the post-titration window are the standard counseling priorities. injection-site reactions are mild and occur in about 3 to 5 percent of patients. headache and fatigue are reported in 5 to 10 percent. hypoglycemia is a low risk as monotherapy but meaningful when combined with sulfonylureas or insulin; both background agents typically need dose reduction at liraglutide initiation.

the boxed warning for thyroid C-cell tumors rests on rodent studies by Bjerre Knudsen and colleagues showing C-cell hyperplasia and medullary thyroid carcinoma at supraphysiologic exposures. long-term human registry surveillance has not produced a clear MTC signal at clinical doses, but the warning remains and personal or family history of MTC and multiple endocrine neoplasia syndrome type 2 are firm contraindications. pancreatitis was tracked specifically in LEADER, which found a non-significant numerical excess; most modern reviews consider the absolute risk small but real. acute kidney injury is dehydration-mediated and highest in elderly patients on diuretics or ACE inhibitors during severe GI illness. rapid weight loss raises gallbladder risk independent of mechanism.

liraglutide is not recommended in pregnancy. the practical advantage of the 13-hour half-life is fast washout (about 3 to 4 days at 5 half-lives), much faster than semaglutide's roughly 5-week washout, which matters for women planning pregnancy. lactation data are limited. the longest robust safety data are LEADER's roughly 4-year follow-up plus 15 years of post-marketing surveillance.

where it fits in peptide therapy

liraglutide is the foundational once-daily GLP-1 receptor agonist. it has been largely superseded by weekly semaglutide and tirzepatide for new prescriptions, but it retains roles in pediatric T2D, in patients planning pregnancy, in cost-sensitive contexts now that generic liraglutide is available, and where the daily dosing rhythm is preferred over the weekly commitment.

the direct successor is semaglutide, which uses a longer C18 fatty diacid and an Aib8 substitution to push the half-life to about 7 days and supports weekly dosing. semaglutide produces roughly twice the weight loss of liraglutide in obesity (about 15 percent at 2.4 mg vs about 6 to 8 percent at 3.0 mg) and now carries a CVOT label from SELECT and a MASH accelerated approval. the dual-agonist successor is tirzepatide, which adds a GIP arm to the GLP-1 backbone and produces about 20 percent weight loss at the 15 mg dose. the investigational triple agonist retatrutide stacks a glucagon arm on top.

the bigger-picture comparisons are with the newer multi-receptor agents. survodutide is an investigational GLP-1 plus glucagon dual agonist with strong phase 2 MASH histology data. cagrilintide paired with semaglutide as CagriSema is the investigational long-acting amylin combination. each of these adds a different second hormone, and the choice across them once they are approved will likely be indication-driven. for foundational biology on incretin signaling, our free peptides and your body module covers the underlying physiology.